MGNX vs PATH · rev $149.5M vs P/E 19, rev $1.61B
MacroGenics Inc (MGNX) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
MacroGenics Inc (MGNX) is a biotechnology company listed on NASDAQ.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported MGNX revenue for 2025-12-31 was $149.5M. Net income was -$74.6M. Revenue was down 0.3% from 2024-12-31 to 2025-12-31. MGNX currently screens at market cap $246.6M.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
MGNX currently screens at market cap $246.6M. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the MGNX and PATH stock pages for the full models.
Not investment advice.